MAPT and Alzheimer disease: In fact, PPARγ signaling exerts several potential beneficial mechanisms in early, as well as in late, AD, as it reduces inflammation, improves metabolic processes, and may directly reduce levels of pathogenic amyloid beta and hyperphosphorylated tau.